GlassScriptPhysician profile
John Carl Clements
NPI 1881612364
$6,441.30
in general payments reported to CMS, 2019-2025
37 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $703 · 2021: $654 · 2022: $825 · 2023: $744 · 2024: $1,031 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Travel and Lodging: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.75 |
| Travel and Lodging | $390.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,807.80 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Stryker Corporation | $757.75 | 2024-2025 | Easyfuse, Ortholoc 2 Lapifuse |
| Takeda Pharmaceuticals U.S.A., INC. | $498.58 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.00 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $401.22 | 2022-2025 | |
| Janssen Biotech, INC. | $372.65 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Celgene Corporation | $293.77 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $182.87 | 2019-2025 | |
| Novo Nordisk INC | $180.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $159.66 | 2019-2021 | |
| Braintree Laboratories, INC. | $148.87 | 2019-2024 | Sutab, Suflave |
| Lilly USA, LLC | $111.03 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $93.87 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $91.41 | 2019-2022 | |
| Romark Laboratories, Lc | $89.55 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $89.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $85.88 | 2019-2022 | |
| Pfizer INC. | $72.02 | 2024-2025 | |
| Redhill Biopharma INC. | $71.56 | 2020-2021 | |
| Boston Scientific Corporation | $59.41 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $58.87 | 2024-2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $50.22 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $47.81 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $38.99 | 2024 | Voquezna |
| Olympus America INC. | $28.35 | 2024 | Visiglide |
| Nestle Healthcare Nutrition INC. | $26.70 | 2021-2023 | |
| Fujifilm Healthcare Americas Corporation | $26.41 | 2019 | |
| Organon LLC | $20.90 | 2023-2024 | Hadlima |
| Fresenius Kabi USA, LLC | $20.63 | 2023 | Idacio |
| Astrazeneca Pharmaceuticals LP | $18.24 | 2022 | |
| Ambu INC. | $16.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2023 | Cyltezo |
| Ardelyx, INC. | $14.59 | 2022 | |
| Merck Sharp & Dohme LLC | $14.44 | 2019 | |
| Lucid Diagnostics INC. | $14.07 | 2022 | |
| Shionogi INC | $14.04 | 2019 | |
| Allergan, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.